SLSSELLAS Life Sciences Group, Inc.
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$28M
- 10% YoY
- Market cap
- $2.0B
- Employees
- —
- Net debt / EBITDA
- —
- −$138M net debt
- AI in 10-K
- 0.7
- mentions per 10K words
Takeover score 2 of 13
Fixable underperformance 1 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo$2M medianMedian CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCNo—Over 10% of revenue
- Payouts exceed cash flowNo-14% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo1% of assetsOver 40% of assets
- Shareholder dissentYes77% lowest supportAny vote under 80% support
Buyer economics 1 of 4
- Low revenue per employeeNo—Bottom quartile of its SIC industry
- Quiet on AINo0.7 per 10K words · 27th pctBottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedYes$2.0B market capMarket cap $500M–$5B
Catalysts 0 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo$101K netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $8M | $1M | $0 | — | — | |
| Operating income | −$25M | −$42M | −$38M | −$32M | −$28M | 10% |
| Net income | −$21M | −$41M | −$37M | −$31M | −$27M | 13% |
| Operating cash flow | −$26M | −$24M | −$31M | −$35M | −$28M | 20% |
| Stock-based comp | $1M | $2M | $2M | $2M | $2M | 25% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $101K · 1
- Open-market sells, 12 mo
- $0 · 0
- Net
- $101K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $2M | $4M | 160 | — |
| FY2024 | $1M | $1M | 44 | — |
| FY2023 | $2M | $801K | 45 | — |